Cargando…

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

Several possible mechanisms for the synergistic anti-tumour effects between tumour necrosis factor alpha (TNF-α) and melphalan after isolated limb perfusion (ILP) have been presented. We found a significant sixfold increase in melphalan tumour tissue concentration after ILP when TNF-α was added to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Wilt, J H W, ten Hagen, T L M, de Boeck, G, van Tiel, S T, de Bruijn, E A, Eggermont, A M M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374420/ https://www.ncbi.nlm.nih.gov/pubmed/10737379 http://dx.doi.org/10.1054/bjoc.1999.1032

Ejemplares similares

Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
por: Wilt, J H W de, et al.
Publicado: (1999)

Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions
por: de Wilt, J H W, et al.
Publicado: (2000)

Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity
por: Seynhaeve, A L B, et al.
Publicado: (2002)

Isolated Limb Perfusion with Melphalan and TNF-α in the Treatment of Extremity Sarcoma
por: Verhoef, Cornelis, et al.
Publicado: (2007)

TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
por: van der Veen, A H, et al.
Publicado: (2000)

Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion.
por: Kuppen, P. J., et al.
Publicado: (1997)

Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion
por: van Etten, B, et al.
Publicado: (2003)

TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature
por: Podleska, L E, et al.
Publicado: (2015)

TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature
por: Podleska, L E, et al.
Publicado: (2015)

Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
por: Borel Rinkes, I. H., et al.
Publicado: (1997)

Lack of efficacy of Doxil® in TNF-α-based isolated limb perfusion in sarcoma-bearing rats
por: ten Hagen, T L M, et al.
Publicado: (2004)

Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors
por: van Etten, B, et al.
Publicado: (2004)

Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.
por: Nooijen, P. T., et al.
Publicado: (1996)

Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion.
por: Marinelli, A., et al.
Publicado: (1991)

In vivo isolated kidney perfusion with tumour necrosis factor α (TNF-α) in tumour-bearing rats
por: Veen, A H van der, et al.
Publicado: (1999)

Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery
por: Brunstein, F, et al.
Publicado: (2006)

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
por: Klaase, J. M., et al.
Publicado: (1994)

Isolated Limb Perfusion with Tumor Necrosis Factor Alpha and Melphalan for Locally Advanced Soft Tissue Sarcoma: Three Time Periods at Risk for Amputation
por: van Ginkel, Robert J., et al.
Publicado: (2007)

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
por: Scott, R. N., et al.
Publicado: (1992)

Response of two mouse tumours to hyperthermia with CCNU or melphalan.
por: Joiner, M. C., et al.
Publicado: (1982)

Primary Cutaneous B-cell Lymphoma Leg-type Related to a Tumour Necrosis Factor Alpha Inhibitor
por: BELKAÏD, Samy, et al.
Publicado: (2022)

Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients
por: Johansson, Junko, et al.
Publicado: (2018)

Isolated Hypoxic Hepatic Perfusion with Retrograde Outflow in Patients with Irresectable Liver Metastases; A New Simplified Technique in Isolated Hepatic Perfusion
por: Verhoef, Cornelis, et al.
Publicado: (2008)

Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis
por: Fenton, B M, et al.
Publicado: (2002)

Metabolic effects of tumour necrosis factor alpha in NMRI mice.
por: Mahony, S. M., et al.
Publicado: (1990)

Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.
por: Stratford, I. J., et al.
Publicado: (1988)

Giant solitary fibrous tumour of the liver
por: Terkivatan, Türkan, et al.
Publicado: (2006)

Thermal enhancement of both tumour necrosis factor alpha-induced systemic toxicity and tumour cure in rats.
por: van der Zee, J., et al.
Publicado: (1995)

Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
por: Tsutsumi, Y., et al.
Publicado: (1996)

Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.
por: Horsman, M. R., et al.
Publicado: (1984)

NTRK fusions are extremely rare in bone tumours
por: Lam, Suk Wai, et al.
Publicado: (2021)

Potentiation of melphalan activity against a murine tumour by nitroimidazole compounds.
por: Sheldon, P. W., et al.
Publicado: (1982)

Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast.
por: Pusztai, L., et al.
Publicado: (1994)

Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers
por: Veelken, Rhea, et al.
Publicado: (2021)

Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
por: Biesma, B., et al.
Publicado: (1992)

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.
por: Guchelaar, H. J., et al.
Publicado: (1992)

Melphalan uptake in relation to vascular and extracellular space of human lung-tumour xenografts.
por: Wist, E., et al.
Publicado: (1981)

20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters
por: Deroose, Jan P., et al.
Publicado: (2011)

The neutrophil migration induced by tumour necrosis factor alpha in mice is unaffected by glucocorticoids
por: Cecilio, C. A., et al.
Publicado: (1997)

Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology
por: Tse, Brian W. C., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_14a5fu4r131r7sstbkaqon0dne